446 related articles for article (PubMed ID: 30568427)
1. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.
Chorepsima S; Kechagias KS; Kalimeris G; Triarides NA; Falagas ME
Drug Des Devel Ther; 2018; 12():4059-4066. PubMed ID: 30568427
[TBL] [Abstract][Full Text] [Related]
2. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
[TBL] [Abstract][Full Text] [Related]
3. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
4. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Bilton D; Henig N; Morrissey B; Gotfried M
Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
[TBL] [Abstract][Full Text] [Related]
5. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
[TBL] [Abstract][Full Text] [Related]
6. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients.
Wang S; Zhang A; Yao X
Intern Med J; 2021 Sep; 51(9):1505-1512. PubMed ID: 33469994
[TBL] [Abstract][Full Text] [Related]
8. Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis.
Xu MJ; Dai B
Ther Adv Respir Dis; 2020; 14():1753466620936866. PubMed ID: 32615859
[TBL] [Abstract][Full Text] [Related]
9. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.
Paredes Aller S; Quittner AL; Salathe MA; Schmid A
Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials.
Lim JU; Hong SW; Ko JH
Ther Adv Respir Dis; 2019; 13():1753466619875930. PubMed ID: 31538535
[TBL] [Abstract][Full Text] [Related]
11. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
Dhand R
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.
Laska IF; Crichton ML; Shoemark A; Chalmers JD
Lancet Respir Med; 2019 Oct; 7(10):855-869. PubMed ID: 31405826
[TBL] [Abstract][Full Text] [Related]
13. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
De Soyza A; Aksamit T; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis.
Yang JW; Fan LC; Lu HW; Miao XY; Mao B; Xu JF
Clin Respir J; 2016 Nov; 10(6):731-739. PubMed ID: 25620629
[TBL] [Abstract][Full Text] [Related]
15. Inhaled antibiotics in non-cystic fibrosis bronchiectasis: A meta-analysis.
Xu L; Zhang F; Du S; Yu Q; Chen L; Long LH; Li YM; Jia AH
Pharmazie; 2016 Sep; 71(9):491-498. PubMed ID: 29441843
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Kietzig C; Weimann B
J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):53-63. PubMed ID: 27448179
[TBL] [Abstract][Full Text] [Related]
17. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
[TBL] [Abstract][Full Text] [Related]
18. Eradication of
Blanco-Aparicio M; Saleta Canosa JL; Valiño López P; Martín Egaña MT; Vidal García I; Montero Martínez C
Chron Respir Dis; 2019; 16():1479973119872513. PubMed ID: 31480862
[TBL] [Abstract][Full Text] [Related]
19. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review.
Brodt AM; Stovold E; Zhang L
Eur Respir J; 2014 Aug; 44(2):382-93. PubMed ID: 24925920
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.
Justo JA; Danziger LH; Gotfried MH
Ther Adv Respir Dis; 2013 Oct; 7(5):272-87. PubMed ID: 23690368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
